The human immunodeficiency virus type 1 (hiv 1) market was valued at USD 39.10 billion in 2025, projected to reach USD 41.45 billion in 2026, and is forecast to expand to USD 74.22 billion by 2036 at a 6.0% CAGR. Expanding antiretroviral therapy access, evolving treatment guidelines favoring integrase inhibitor-based regimens, and global scale-up of test-and-treat programs are sustaining consistent demand growth across both established and emerging therapeutic markets.
-market-market-value-analysis.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Market Value Analysis")
| Metric | Details |
|---|---|
| Industry Size (2026) | USD 41.45 billion |
| Industry Value (2036) | USD 74.22 billion |
| CAGR (2026-2036) | 6.0% |
Source: Future Market Insights, 2026
Treatment paradigm consolidation around single-tablet regimen formulations continues to reshape competitive dynamics across the HIV therapeutics market. FMI analysts note that integrase strand transfer inhibitor-based combinations have displaced protease inhibitor backbones as first-line standard of care in most national treatment guidelines. Generic competition in older drug classes is compressing revenue in mature markets while long-acting injectable formulations create new premium pricing tiers that partially offset volume-driven price erosion.
Country-level growth projections reflect treatment coverage gaps, generic penetration timelines, and regulatory pathway differences. China at 8.1%, India at 7.5%, Germany at 6.9%, France at 6.3%, UK at 5.7%, USA at 5.1%, Brazil at 4.5%. China leads expansion driven by central government commitment to achieve UNAIDS 95-95-95 targets through accelerated treatment initiation and domestic generic production scaling. India maintains strong growth through national program procurement of affordable integrase inhibitor-based regimens and expanded testing infrastructure. Germany and France sustain growth through early adoption of long-acting injectable regimens and comprehensive insurance coverage. The United Kingdom and United States reflect mature markets with growth driven by treatment innovation uptake and adherence program optimization. Brazil expands through public health system procurement and domestic manufacturing capacity development.
The Human Immunodeficiency Virus Type 1 (HIV-1) Market encompasses prescription antiretroviral therapeutics used in the treatment and clinical management of HIV-1 infection. Drug classes include integrase strand transfer inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists. Products span originator branded formulations, generic equivalents, single-tablet regimens, fixed-dose combinations, and long-acting injectable preparations prescribed across first-line, second-line, and salvage therapy settings.
Market scope includes prescription antiretroviral drug revenue across all approved drug classes for HIV-1 treatment, encompassing originator and generic formulations, single-tablet and multi-tablet regimens, and long-acting injectable products. Revenue from first-line, second-line, and salvage therapy prescriptions across all regional markets is included.
The scope excludes HIV-2 specific therapeutic products, pre-exposure prophylaxis formulations, HIV diagnostic testing platforms and assay revenue, antiretroviral manufacturing equipment, and clinical trial expenditure for investigational compounds not yet approved for commercial distribution.
One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 36.9.0 million people were living with HIV infection in 2024, with 1.5 million [1.1 million-2.0 million] new HIV infections.
According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV-1 patients' access to treatment and assessment. This is expected to fuel the global HIV-1 market.
The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.
Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.
Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.
As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.
-market-cagr-analysis-by-country.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Cagr Analysis By Country")
-market-country-value-analysis.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Country Value Analysis")
North America's dominance is due to the high prevalence of HIV infection
With a market share of USD 39.1 Billion in 2026, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2039.1, an estimated 29.2 million people were living with HIV at the end of 2020.
With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.
Because of its dense population, the Asia Pacific market is the fastest-growing region
Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.
For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a USD 36.9 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2024. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.
-market-analysis-by-drug-class.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Analysis By Drug Class")
Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients
As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2026, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).
The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the late innovative pharmaceutical launches
-market-analysis-by-company.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Analysis By Company")
Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.
-market-breakdown-by-drug-class,-,-and-region.webp "Human Immunodeficiency Virus Type 1 (hiv 1) Market Breakdown By Drug Class, , And Region")
| Metric | Value |
|---|---|
| Quantitative Units | USD 41.45 billion to USD 74.22 billion, at a CAGR of 6.0% |
| Market Definition | The Human Immunodeficiency Virus Type 1 (HIV-1) Market encompasses prescription antiretroviral therapeutics used in the treatment and clinical management of HIV-1 infection. Drug classes include integrase strand transfer inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists. Products span originator branded formulations, generic equivalents, single-tablet regimens, fixed-dose combinations, and long-acting injectable preparations prescribed across first-line, second-line, and salvage therapy settings. |
| Segmentation | Drug Class: Integrase Inhibitors, Nucleoside-Analog Reverse Transcriptase Inhibitor, Non-Nucleoside Reverse Transcriptase Inhibitor, Entry and Fusion Inhibitors, Protease Inhibitors, Coreceptor Antagonists |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa |
| Countries Covered | China, India, Germany, France, UK, USA, Brazil, and 40 plus countries |
| Key Companies Profiled | Gilead Sciences, Inc., AbbVie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla, Inc., Genentech, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi |
| Forecast Period | 2026 to 2036 |
| Approach | Forecasting models apply a bottom-up methodology starting with product-level revenue metrics and cross-validate projections against enterprise spending guidance and regulatory adoption timelines. |
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.
Demand for human immunodeficiency virus type 1 (hiv 1) market in the global market is estimated to be valued at USD 41.45 billion in 2026.
Market size for human immunodeficiency virus type 1 (hiv 1) market is projected to reach USD 74.22 billion by 2036.
Demand for human immunodeficiency virus type 1 (hiv 1) market is expected to grow at a CAGR of 6.0% between 2026 and 2036.
Integrase Inhibitors accounts for 35.7% share in 2026, leading the drug class segment based on FMI analysis.
China is projected to grow at a CAGR of 8.1% during 2026 to 2036, driven by targeted infrastructure investments and favorable policy frameworks supporting market expansion.
The Human Immunodeficiency Virus Type 1 (HIV-1) Market encompasses prescription antiretroviral therapeutics used in the treatment and clinical management of HIV-1 infection. Drug classes include integrase strand transfer inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists.
Forecasting models apply a bottom-up methodology starting with product-level and service-level revenue metrics and cross-validate projections against publicly reported enterprise guidance and regulatory adoption data.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Human Immunodeficiency Virus Type 1 (HIV 1) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
